✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Biocon Ltd.

BIOCON

Market Cap
₹67,713 Cr.
P/E
175.61

Biocon Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
67,713 Cr
PE
PE
175
Prom Holding
Prom Holding
44.91 %
ROE (%)
ROE (%)
4.68
ROCE (%)
ROCE (%)
6.08
Div Yield (%)
Div Yield (%)
0.12
Sales
Sales
-
OPM (%)
OPM (%)
20.31 %
Debt to Equity
Debt to Equity
0.84
Institutions
Institutions
31.59 %
Individual < 2 lac
Individual < 2 lac
5.77 %
No. of Shareholders
No. of Shareholders
3.87 L
View more
Edit Ratio's

About

Biocon is a global biopharmaceutical company focused on making complex therapies for chronic c… Read more
Low
328
52W Range
High
425
  • Biocon
  • Concord Biotech
  • Advanced Enzyme
  • TJI Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

1.52 %
(as of Jul 22)
Historic
Anti - Diabetes - Market Share
0.27 %
(as of Jul 22)
Historic
Anti-Infectives - Market Share
4.21 %
(as of Nov 21)
Historic
Antineo Plastic - Market Share
1.04 %
(as of Nov 21)
Historic
Blood Related - Market Share
27 %
(as of Mar 19)
Source/Historic
CANMAb - Market Share
0.05 %
(as of Jul 22)
Historic
Cardiovascular - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

    locked
    Select a Metric
    • Domestic Sales Growth - YoY (%)
      Source
    • Fermentation Capacity (KL)
      Source
    • R&D as a % of Total Sales (%)
      Source

    Peer Comparison

    Brands

    CANMAb
    Insugen

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Sobha Ltd.
    • Alkyl Amines Chemicals Ltd.
    • B.L. Kashyap and Sons Ltd.

    FAQs on Biocon Ltd. Business

    Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe.

    Biocon major competitors are Concord Biotech, Advanced Enzyme, Fermenta Biotech, Glenmark Pharma, Alkem Laboratories, Abbott India, Aurobindo Pharma.
    Market Cap of Biocon is ₹65,185 Crs.
    While the median market cap of its peers are ₹57,157 Crs.

    Biocon seems to be less financially stable compared to its competitors.
    Altman Z score of Biocon is 1.82 and is ranked 8 out of its 8 competitors.

    View FAQ's On Shareprice

    Discussions & Analysis

    Biocon Ltd.
    Biocon Biologics Serum Lifesciences collaboration call notes - JST Investments
    View the discussion on ValuePickr
    Industrial Biotechnology - Insulin Production - NPTEL
    How Biocon produces Insulin using rDNA Technology - Bio Science
    Biocon - Viatris Takeover Primer - JST Investments
    Biocon Biologics - An effort to understand the biosimilar business - Dr Midhun
    Biotech to Billions: THINK BIG, NEVER GIVE UP & DISRUPT - G2G Ajay
    Pharmaceuticals
    GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity
    Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    Nutraceuticals- Industry Overview - Value Educator
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Pharma Compliance In-Depth - Amit Rajan
    Deep Dive into Pharma Sector - Omkara Capital
    How The Pharma Industry Works - PPFAS
    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material